Skip Nav Destination
Close Modal
1-20 of 20 Search Results for
amp
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Image
in Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
> Journal of Health Politics, Policy and Law
Published: 01 April 2016
Figure 2 Trends in Average Firm R&D and SG&A Expenditures (in Millions of Dollars), 1999–2009 Source : Authors' analyses of data from firms' 10-K filings with the Securities and Exchange Commission, available in Mergent or Compustat, for firms with at least one NDA approval from the FDA...
More
Image
in Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
> Journal of Health Politics, Policy and Law
Published: 01 April 2016
Figure 3 Estimated Impact of Increased Lagged and Current SG&A and R&D on NDA Approvals Source : Authors' analyses of data for publicly traded firms with complete financial data, as described in the “Data” section. Notes : R&D=research and development; SG&A=selling, general, a...
More
Image
in Reduction in Medicaid Rebates Paid by Pharmaceutical Manufacturers for Outpatient Infused, Injected, Implanted, Inhaled, or Instilled Drugs: The 5i Loophole
> Journal of Health Politics, Policy and Law
Published: 01 December 2022
Figure 2 Difference in estimated 2017 Medicaid rebates for Humira under standard AMP and 5i AMP methodologies. Notes : AMP = average manufacturer price. The figure shows the difference in Medicaid rebates per unit of Humira in 2017 between the standard methodology (left) and the 5i methodology
More
Image
in Reduction in Medicaid Rebates Paid by Pharmaceutical Manufacturers for Outpatient Infused, Injected, Implanted, Inhaled, or Instilled Drugs: The 5i Loophole
> Journal of Health Politics, Policy and Law
Published: 01 December 2022
Figure 3 Difference in AMP and Medicaid rebates per unit of Humalog under standard AMP and 5i AMP methodologies, 2013–2017. Panel A Difference in AMP estimates. Panel B Difference in Medicaid rebates. Notes : PBM = pharmaceutical benefit manager; AMP = average manufacturer price. 5i AMP
More
Journal Article
J Health Polit Policy Law 11567660.
Published: 27 September 2024
Journal Article
J Health Polit Policy Law (2022) 47 (6): 835–851.
Published: 01 December 2022
...Figure 2 Difference in estimated 2017 Medicaid rebates for Humira under standard AMP and 5i AMP methodologies. Notes : AMP = average manufacturer price. The figure shows the difference in Medicaid rebates per unit of Humira in 2017 between the standard methodology (left) and the 5i methodology...
FIGURES
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2021) 46 (3): 435–465.
Published: 01 June 2021
FIGURES
Journal Article
J Health Polit Policy Law (2015) 40 (1): 195–219.
Published: 01 February 2015
FIGURES
Journal Article
J Health Polit Policy Law (2018) 43 (1): 5–18.
Published: 01 February 2018
...-based pricing by adjusting the unit-price requirement, exercise enforcement discretion with respect to the AMP, and relax the best-price rule for Medicare demonstration projects. CMS may nonetheless have some flexibility on the margins. Recall that Medicaid will pay either a drug's best price...
Journal Article
J Health Polit Policy Law (2024) 49 (3): 473–493.
Published: 01 June 2024
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2019) 44 (6): 919–935.
Published: 01 December 2019
Journal Article
J Health Polit Policy Law (2023) 48 (5): 713–760.
Published: 01 October 2023
FIGURES
| View All (7)
Journal Article
J Health Polit Policy Law (2023) 48 (6): 951–968.
Published: 01 December 2023
FIGURES
Journal Article
J Health Polit Policy Law (2021) 46 (2): 305–355.
Published: 01 April 2021
FIGURES
| View All (6)
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2022) 47 (3): 293–318.
Published: 01 June 2022
FIGURES
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2023) 48 (3): 317–350.
Published: 01 June 2023
FIGURES
| View All (5)
Journal Article
J Health Polit Policy Law (1983) 8 (2): 320–351.
Published: 01 April 1983
.... Prices of Most Common Drugs Within the German Market, in Spain
and West Germany
Drug Pack-Size Spain" FRG
Euglucon 30 tab. DM 6.75 DM 23.90
Hydergin 6 amp. 2.85 7.22b
Adumbran 25 tab...
Journal Article
J Health Polit Policy Law (2017) 42 (1): 53–71.
Published: 01 February 2017
... .” Prescriptions for Excellence in Health Care 9 ( January ). jdc.jefferson.edu/cgi/viewcontent.cgi?article=1075&amp;context=pehc . Buchanan David R. 2008 . “ Autonomy, Paternalism and Justice: Ethical Priorities in Public Health .” American Journal of Public Health 98 , no. 1 : 15 – 21...
Journal Article
J Health Polit Policy Law (2024) 49 (4): 631–664.
Published: 01 August 2024
...&A Activity Recorded in 2022, According to Acquisition Data from LevinPro HC .” PRWeb, January 13 . https://www.prweb.com/releases/record-breaking-health-care-m-amp-a-activity-recorded-in-2022-according-to-acquisition-data-from-levinpro-hc-821886582.html . LevinPro HC . 2023b . “ Physician Medical...
FIGURES
Journal Article
J Health Polit Policy Law (1982) 7 (1): 163–196.
Published: 01 February 1982
..., Policy and Law
ture assistants. Unlike Nevada, Rhode Island does not recognize the practice of herbal
medicine. A five-member Board of Acupuncture administers the law, guided by detailed
regulations similar to Nevada’s (R.Z. Rules and Regs. for the Licensing of Doctors of
Amp...
